Neratinib Included In NCCN Guidelines For Specific HER2-Negative Breast Cancers
In recommendations released on 2 February 2023, the National Comprehensive Cancer Network (NCCN) recommends that doctors consider neratinib for patients with HER2-negative metastatic breast cancer, regardless of their estrogen receptor status.